# A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

> **NCT06899802** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bavarian Nordic** · enrollment: 411 (actual)

## Conditions studied

- Encephalitis

## Interventions

- **BIOLOGICAL:** MVA-BN-WEV
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06899802
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2027-02
- **Final completion:** 2027-03
- **Target enrollment:** 411 (ACTUAL)
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06899802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06899802, "A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06899802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*